Cargando…
Systemic sclerosis in the time of COVID-19
The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In addition to the general effect on society and health-care systems, patients with systemic sclerosis and their physicians face specific challenges related to the chronic nature of their disease, the involvement of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302939/ https://www.ncbi.nlm.nih.gov/pubmed/35891634 http://dx.doi.org/10.1016/S2665-9913(22)00130-8 |
_version_ | 1784751740711600128 |
---|---|
author | Hoffmann-Vold, Anna-Maria Distler, Oliver Bruni, Cosimo Denton, Christopher P de Vries-Bouwstra, Jeska Matucci Cerinic, Marco Vonk, Madelon C Gabrielli, Armando |
author_facet | Hoffmann-Vold, Anna-Maria Distler, Oliver Bruni, Cosimo Denton, Christopher P de Vries-Bouwstra, Jeska Matucci Cerinic, Marco Vonk, Madelon C Gabrielli, Armando |
author_sort | Hoffmann-Vold, Anna-Maria |
collection | PubMed |
description | The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In addition to the general effect on society and health-care systems, patients with systemic sclerosis and their physicians face specific challenges related to the chronic nature of their disease, the involvement of multiple organs, and the use of immunosuppressive treatments. Data from registries and single centre cohorts indicate that the risk of contracting SARS-CoV-2 does not seem to increase substantially in people with systemic sclerosis; conversely, severe COVID-19 outcomes are seen more frequently in these patients than in the general population. Vaccination against SARS-CoV-2 is therefore highly recommended for patients with systemic sclerosis; however, no specific recommendations are available regarding the different vaccine platforms. Both patients and physicians should be aware that the effectiveness of vaccines might be reduced in patients taking immunosuppressive therapy, because antibody responses might be blunted, specifically in patients treated with rituximab and mycophenolate mofetil. |
format | Online Article Text |
id | pubmed-9302939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93029392022-07-22 Systemic sclerosis in the time of COVID-19 Hoffmann-Vold, Anna-Maria Distler, Oliver Bruni, Cosimo Denton, Christopher P de Vries-Bouwstra, Jeska Matucci Cerinic, Marco Vonk, Madelon C Gabrielli, Armando Lancet Rheumatol Review The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In addition to the general effect on society and health-care systems, patients with systemic sclerosis and their physicians face specific challenges related to the chronic nature of their disease, the involvement of multiple organs, and the use of immunosuppressive treatments. Data from registries and single centre cohorts indicate that the risk of contracting SARS-CoV-2 does not seem to increase substantially in people with systemic sclerosis; conversely, severe COVID-19 outcomes are seen more frequently in these patients than in the general population. Vaccination against SARS-CoV-2 is therefore highly recommended for patients with systemic sclerosis; however, no specific recommendations are available regarding the different vaccine platforms. Both patients and physicians should be aware that the effectiveness of vaccines might be reduced in patients taking immunosuppressive therapy, because antibody responses might be blunted, specifically in patients treated with rituximab and mycophenolate mofetil. Published by Elsevier Ltd. 2022-08 2022-07-21 /pmc/articles/PMC9302939/ /pubmed/35891634 http://dx.doi.org/10.1016/S2665-9913(22)00130-8 Text en Crown Copyright © 2022 Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Hoffmann-Vold, Anna-Maria Distler, Oliver Bruni, Cosimo Denton, Christopher P de Vries-Bouwstra, Jeska Matucci Cerinic, Marco Vonk, Madelon C Gabrielli, Armando Systemic sclerosis in the time of COVID-19 |
title | Systemic sclerosis in the time of COVID-19 |
title_full | Systemic sclerosis in the time of COVID-19 |
title_fullStr | Systemic sclerosis in the time of COVID-19 |
title_full_unstemmed | Systemic sclerosis in the time of COVID-19 |
title_short | Systemic sclerosis in the time of COVID-19 |
title_sort | systemic sclerosis in the time of covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302939/ https://www.ncbi.nlm.nih.gov/pubmed/35891634 http://dx.doi.org/10.1016/S2665-9913(22)00130-8 |
work_keys_str_mv | AT hoffmannvoldannamaria systemicsclerosisinthetimeofcovid19 AT distleroliver systemicsclerosisinthetimeofcovid19 AT brunicosimo systemicsclerosisinthetimeofcovid19 AT dentonchristopherp systemicsclerosisinthetimeofcovid19 AT devriesbouwstrajeska systemicsclerosisinthetimeofcovid19 AT matuccicerinicmarco systemicsclerosisinthetimeofcovid19 AT vonkmadelonc systemicsclerosisinthetimeofcovid19 AT gabrielliarmando systemicsclerosisinthetimeofcovid19 |